220 related articles for article (PubMed ID: 36607794)
1. Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca
Kadosaka T; Watanabe M; Natsui H; Koizumi T; Nakao M; Koya T; Hagiwara H; Kamada R; Temma T; Karube F; Fujiyama F; Anzai T
Am J Physiol Heart Circ Physiol; 2023 Mar; 324(3):H341-H354. PubMed ID: 36607794
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin improves left ventricular diastolic function of db/db mice.
Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.
Mustroph J; Wagemann O; Lücht CM; Trum M; Hammer KP; Sag CM; Lebek S; Tarnowski D; Reinders J; Perbellini F; Terracciano C; Schmid C; Schopka S; Hilker M; Zausig Y; Pabel S; Sossalla ST; Schweda F; Maier LS; Wagner S
ESC Heart Fail; 2018 Aug; 5(4):642-648. PubMed ID: 30117720
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
5. Calcium-calmodulin-dependent protein kinase mediates the intracellular signalling pathways of cardiac apoptosis in mice with impaired glucose tolerance.
Federico M; Portiansky EL; Sommese L; Alvarado FJ; Blanco PG; Zanuzzi CN; Dedman J; Kaetzel M; Wehrens XHT; Mattiazzi A; Palomeque J
J Physiol; 2017 Jun; 595(12):4089-4108. PubMed ID: 28105734
[TBL] [Abstract][Full Text] [Related]
6. Hyperglycemia Acutely Increases Cytosolic Reactive Oxygen Species via
Lu S; Liao Z; Lu X; Katschinski DM; Mercola M; Chen J; Heller Brown J; Molkentin JD; Bossuyt J; Bers DM
Circ Res; 2020 May; 126(10):e80-e96. PubMed ID: 32134364
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1.
Silva Dos Santos D; Turaça LT; Coutinho KCDS; Barbosa RAQ; Polidoro JZ; Kasai-Brunswick TH; Campos de Carvalho AC; Girardi ACC
Sci Rep; 2023 May; 13(1):8689. PubMed ID: 37248416
[TBL] [Abstract][Full Text] [Related]
8. Left ventricular deformation associated with cardiomyocyte Ca(2+) transients delay in early stage of low-dose of STZ and high-fat diet induced type 2 diabetic rats.
Liu XY; Liu FC; Deng CY; Zhang MZ; Yang M; Xiao DZ; Lin QX; Cai ST; Kuang SJ; Chen J; Chen SX; Zhu JN; Yang H; Rao F; Fu YH; Yu XY
BMC Cardiovasc Disord; 2016 Feb; 16():41. PubMed ID: 26879576
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function.
Wang J; Huang X; Liu H; Chen Y; Li P; Liu L; Li J; Ren Y; Huang J; Xiong E; Tian Z; Dai X
Oxid Med Cell Longev; 2022; 2022():1122494. PubMed ID: 35585884
[TBL] [Abstract][Full Text] [Related]
10. Interval training normalizes cardiomyocyte function, diastolic Ca2+ control, and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy.
Stølen TO; Høydal MA; Kemi OJ; Catalucci D; Ceci M; Aasum E; Larsen T; Rolim N; Condorelli G; Smith GL; Wisløff U
Circ Res; 2009 Sep; 105(6):527-36. PubMed ID: 19679837
[TBL] [Abstract][Full Text] [Related]
11. Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy.
Fricovsky ES; Suarez J; Ihm SH; Scott BT; Suarez-Ramirez JA; Banerjee I; Torres-Gonzalez M; Wang H; Ellrott I; Maya-Ramos L; Villarreal F; Dillmann WH
Am J Physiol Regul Integr Comp Physiol; 2012 Oct; 303(7):R689-99. PubMed ID: 22874425
[TBL] [Abstract][Full Text] [Related]
12. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
13. Phospholamban ablation rescues the enhanced propensity to arrhythmias of mice with CaMKII-constitutive phosphorylation of RyR2 at site S2814.
Mazzocchi G; Sommese L; Palomeque J; Felice JI; Di Carlo MN; Fainstein D; Gonzalez P; Contreras P; Skapura D; McCauley MD; Lascano EC; Negroni JA; Kranias EG; Wehrens XH; Valverde CA; Mattiazzi A
J Physiol; 2016 Jun; 594(11):3005-30. PubMed ID: 26695843
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy.
Madonna R; Moscato S; Cufaro MC; Pieragostino D; Mattii L; Del Boccio P; Ghelardoni S; Zucchi R; De Caterina R
Cardiovasc Res; 2023 May; 119(5):1175-1189. PubMed ID: 36627733
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice.
Xue M; Li T; Wang Y; Chang Y; Cheng Y; Lu Y; Liu X; Xu L; Li X; Yu X; Sun B; Chen L
Clin Sci (Lond); 2019 Aug; 133(15):1705-1720. PubMed ID: 31337673
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
[TBL] [Abstract][Full Text] [Related]
17. Roles of impaired intracellular calcium cycling in arrhythmogenicity of diabetic mouse model.
Chou CC; Ho CT; Lee HL; Chu Y; Yen TH; Wen MS; Lin SF; Lee CH; Chang PC
Pacing Clin Electrophysiol; 2017 Oct; 40(10):1087-1095. PubMed ID: 28842915
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases α-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts.
Zhang H; Uthman L; Bakker D; Sari S; Chen S; Hollmann MW; Coronel R; Weber NC; Houten SM; van Weeghel M; Zuurbier CJ
Front Cardiovasc Med; 2020; 7():592233. PubMed ID: 33344518
[No Abstract] [Full Text] [Related]
19. Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes.
Ng KM; Lau YM; Dhandhania V; Cai ZJ; Lee YK; Lai WH; Tse HF; Siu CW
Sci Rep; 2018 Oct; 8(1):14872. PubMed ID: 30291295
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats.
Lee TI; Chen YC; Lin YK; Chung CC; Lu YY; Kao YH; Chen YJ
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
